Market news

Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $69.12, according

Scholar Rock Holding Corporation (NASDAQ:SRRK) secured FDA approval on September 11 for ISEMBYLD, apitegromab-mstn, to treat spinal muscular atrophy in adults and children aged two and older currently receiving survival motor neuron 2 (SMN2)-targeted therapy. Approval opens a commercial opportunity built around adding muscle-directed treatment to existing care. The investment question now shifts to how […]

FDA approval of Scholar Rock’s ISEMBYLD (apitegromab) for SMA drives a Strong Buy case, with $2B+ market upside and EU/JP catalysts. Click for more on SRRK stock.

Scholar Rock (SRRK) stock slides as Barclays downgrades the company despite FDA approval of its spinal muscular atrophy drug, Isembyld. Read more here.

Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $69.62, according

The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older. The decision makes ISEMBYLD the first muscle-targeted therapy to demonstrate motor...

Scholar Rock Holding Corp (NASDAQ:SRRK) shares rose 9. 1% in pre-market trading to $60.

Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.

Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $65.60, according

CAMBRIDGE, Mass., September 11, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targete

CAMBRIDGE, Mass., August 27, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences:

Scholar Rock Holding stock has delivered an extremely strong multi year return, yet the latest valuation checks suggest the current share price may already be baking in a lot of optimism. After such a sharp move, the key issue for investors is whether the recent rally leaves much room for error. Over the past 3 years the stock has returned roughly 8.3x, which is a very large gain and puts extra focus on whether the present price still reflects a reasonable long term payoff. Progress with...

Scholar Rock Holding (SRRK) updated investors after shifting apitegromab’s commercial fill finish work away from Catalent Indiana following FDA inspection issues, while confirming that the FDA is continuing its review, a revised European filing is underway, and a Japanese submission is planned without new trials. See our latest analysis for Scholar Rock Holding. Investor attention around Scholar Rock Holding has coincided with strong recent momentum, with a 7 day share price return of 7.58%,...

Earlier this week, Scholar Rock announced it has removed Catalent Indiana from all commercial fill-finish roles for apitegromab, with the FDA continuing to review its U.S. BLA using an alternate, previously inspected facility and the company preparing for launch upon a potential decision by the September 30, 2026 PDUFA date. At the same time, the company reset its global regulatory plan by withdrawing and planning to resubmit its European filing with the new facility, while securing PMDA...

Scholar Rock (SRRK) said Friday that, under guidance from the FDA, it has removed Novo Nordisk's (NV

CAMBRIDGE, Mass., August 21, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced it has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for the treatment of spinal muscular atrophy (SMA) in

Scholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitted biologics license application supported by an alternate fill-finish manufacturing

Two healthcare players, Scholar Rock Holding Corporation (NASDAQ:SRRK) and Novo Nordisk A/S (NYSE:NVO), find their near-term narratives intertwined over manufacturing compliance. One is smoothly navigating a supply chain hurdle ahead of a critical drug approval, while the other just delivered a complicated financial quarter. The contrast reveals how investors weigh proactive execution against noisy financial […]

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

CAMBRIDGE, Mass., August 14, 2026--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 14,889 shares of common stock and inducement restricted stock units, covering an aggregate of 37,058 shares of its common stock.